|
|
Volumn 34, Issue 12, 2011, Pages 1773-
|
|
Biological and Pharmaceutical Bulletin: Foreword
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CELL SURFACE RECEPTOR;
GROWTH FACTOR;
IMATINIB;
MITOGEN ACTIVATED PROTEIN KINASE;
PROTEIN TYROSINE KINASE;
TRASTUZUMAB;
TYROSINE KINASE RECEPTOR;
VASCULOTROPIN;
PROTEIN KINASE INHIBITOR;
SIGNAL PEPTIDE;
ANGIOGENESIS;
BREAST CANCER;
CANCER CELL;
CANCER INHIBITION;
CANCER PATIENT;
CANCER THERAPY;
CELL PROLIFERATION;
CELL SURVIVAL;
CELL VIABILITY;
CHRONIC MYELOID LEUKEMIA;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG TARGETING;
DRUG USE;
EDITORIAL;
ENZYME ACTIVITY;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
MALIGNANT NEOPLASTIC DISEASE;
MICROARRAY ANALYSIS;
PROTEIN EXPRESSION;
RECEPTOR BINDING;
SIGNAL TRANSDUCTION;
UNSPECIFIED SIDE EFFECT;
DRUG ANTAGONISM;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
NEOPLASM;
ANTINEOPLASTIC AGENTS;
HUMANS;
INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
SIGNAL TRANSDUCTION;
|
|
EID: 83255164202
PISSN: 09186158
EISSN: 13475215
Source Type: Journal
DOI: 10.1248/bpb.34.1773 Document Type: Editorial |
|
Times cited : (9)
|
|
References (0)
|
